Where I see patients (1)
My reviews
Selected research
-
Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States.
Blood advances
-
Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.
Blood
-
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.
Blood
4.9